NCT02181088View on ClinicalTrials.gov

A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of New Plasmodium Falciparum Malaria Vaccine Candidates ChAd63 RH5 Alone and With MVA RH5

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
MalariaPlasmodium Falciparum
Interventions
BIOLOGICAL

ChAd63 RH5 low dose

ChAd63 RH5 at 5 x 10\^9 vp

BIOLOGICAL

ChAd63 RH5 full dose

ChAd63 RH5 at 5 x 10\^10 vp

BIOLOGICAL

MVA RH5 low dose

MVA RH5 at 1 x 10\^8 pfu

BIOLOGICAL

MVA RH5 full dose

MVA RH5 at 2 x 10\^8 pfu

Trial Locations (2)

OX3 7LE

Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford

Unknown

Wellcome Trust CRF, Southampton General Hospital, University of Southampton, Southampton

All Listed Sponsors
collaborator

European Commission

OTHER

lead

University of Oxford

OTHER

NCT02181088 - A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of New Plasmodium Falciparum Malaria Vaccine Candidates ChAd63 RH5 Alone and With MVA RH5 | Biotech Hunter | Biotech Hunter